Back to Search Start Over

Effect of pentoxifylline and tocopherol on radiation proctitis/enteritis.

Authors :
Hille A
Christiansen H
Pradier O
Hermann RM
Siekmeyer B
Weiss E
Hilgers R
Hess CF
Schmidberger H
Source :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2005 Sep; Vol. 181 (9), pp. 606-14.
Publication Year :
2005

Abstract

Background and Purpose: Chronic radiation proctitis/enteritis is a relevant complication of pelvic irradiation, which is still mainly treated by supportive measures only. There is some evidence that the combined treatment with pentoxifylline and tocopherol might alter the pathogenesis of radiation-induced fibrosis. In a retrospective analysis the clinical benefit of the treatment with pentoxifylline/tocopherol on radiation-induced proctitis/enteritis was evaluated, compared to supportive care only.<br />Patients and Methods: Of 30 patients with radiation-induced proctitis/enteritis grade I-II according to the RTOG/EORTC toxicity criteria, 21 were treated with pentoxifylline and tocopherol. Depending on physician's decision nine patients received symptomatic treatment only.<br />Results: With pentoxifylline/tocopherol treatment 15/21 patients (71%) experienced a relief of their symptoms. A reduction from grade I/II to grade 0 toxicity was observed in seven and from grade II to grade I toxicity in eight patients. No improvement was seen in six patients. The median time to improvement with pentoxifylline and tocopherol treatment was 28 weeks. In three of nine patients who were treated supportively only, deterioration of symptoms occurred. Three patients experienced no amelioration, and three patients with grade I toxicity experienced a spontaneous relief of their symptoms (33%).<br />Conclusion: The combination treatment with pentoxifylline and tocopherol seems to have a benefit in patients with grade I-II radiation-induced proctitis/enteritis. The optimal schedule of treatment duration is not yet clear. From the observations made in this study it is assumed the treatment should be given for 6-12 months at least. A prospective phase II study should be undertaken to evaluate optimal treatment duration.

Details

Language :
English
ISSN :
0179-7158
Volume :
181
Issue :
9
Database :
MEDLINE
Journal :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Publication Type :
Academic Journal
Accession number :
16170489
Full Text :
https://doi.org/10.1007/s00066-005-1390-y